Are SPACs Better Than Traditional IPOs?

Outcome Capital’s Managing Director Paul Mieyal, Ph.D., CFA was interviewed by BioSpace for his views on the recent popularity of SPACs in the biotech space.  The interview covers historical perspective, current market dynamics, and outlook for the next year.

View Resource

Amid Broader Market Pressures, Dx M&A Deals See Downturn in First Half of 2022

COVID-19 brought significant attention and investment to the diagnostic industry. Coming out of the pandemic new pressures and challenges await. Director Craig Steger shares his views and insights on how firms must be strategic and agile in this new paradigm.

View Resource

Dx IPOs Plummet, SPAC Market Recedes Among Macroeconomic Difficulties

Managing Director’s Oded Ben-Joseph, PhD, and Paul Mieyal, PhD, were interviewed by 360Dx for their views on capital markets’ current receptiveness towards COVID diagnostics companies and the viability of SPAC’s for life sciences firms.

View Resource

Biotech Startups: How to Succeed in a COVID-19 World

Navigating uncharted waters, biotech investors, executives and entrepreneurs are finding unique challenges (and opportunities) in a COVID-19 world. Contributing author, Outcome Capital’s Dr. Oded Ben-Joseph, Managing Director and Co-Founder of the Life Sciences Practice.

View Resource

BIO18: Pfizer’s Bourla on Volume vs. Value & a Little Dealmaking Advice from Outcome Capital

Partnerships and the move to value dominated the chatter at the BIO International Convention’s 25th annual partnering meeting on Monday in the life science hub of Boston.

View Resource

Active VCs vs. Zombies: Dysfunctional Boards That Mess With M&A

Investors want to know: Will Big Pharma go bargain hunting, do a little M&A? Will it lift my biotech portfolio out of the gutter? Multiple factors are always at work. At the most basic level, pharma still needs to acquire new products to stay afloat. Little biotechs who create things need to be acquired, or go public, to reward their investors. Those facts never change. But there’s another powerful, and dark, force creating havoc in many biotech boardrooms. People who have witnessed it don’t like to talk about it. When they do, it’s in hushed tones…

View Resource

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Contact Us

  • Boston

    99 High St. Suite 2900, Boston, MA 02110
    (617) 431-2278